Cellectis (NASDAQ:CLLS) Stock Crosses Above 50-Day Moving Average - Time to Sell?

Key Points

• Cellectis S.A. shares recently crossed above their 50-day moving average of $2.25, reaching a high of $2.68 during trading.
• Analysts have cut the target price for Cellectis from $5.00 to $4.00, with a current average rating of "Buy" and a consensus price target at $4.00.
• The company reported a quarterly loss with an earnings per share (EPS) of ($0.24), missing estimates, despite generating revenue of $18.19 million which surpassed expectations.

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $2.25 and traded as high as $2.68. Cellectis shares last traded at $2.57, with a volume of 35,096 shares.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on CLLS shares. Wall Street Zen cut Cellectis from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Barclays decreased their price target on Cellectis from $5.00 to $4.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $4.00.

Cellectis Price Performance

The stock has a market cap of $142.84 million, a price-to-earnings ratio of -3.13 and a beta of 3.03. The company has a 50 day simple moving average of $2.31 and a 200-day simple moving average of $1.72. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.58.

Cellectis (NASDAQ:CLLS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). Cellectis had a negative return on equity of 68.05% and a negative net margin of 100.69%.The business had revenue of $18.19 million for the quarter, compared to the consensus estimate of $10.07 million. Research analysts expect that Cellectis S.A. will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Cellectis

Several institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC raised its holdings in shares of Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 26,461 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Cellectis by 228.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company's stock worth $5,856,000 after acquiring an additional 3,284,409 shares during the last quarter. Long Focus Capital Management LLC raised its holdings in shares of Cellectis by 2.2% in the 1st quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock worth $5,849,000 after acquiring an additional 100,000 shares during the last quarter. OLD Mission Capital LLC acquired a new stake in shares of Cellectis in the 1st quarter worth about $31,000. Finally, Millennium Management LLC purchased a new stake in Cellectis in the 4th quarter valued at about $962,000. Institutional investors and hedge funds own 63.90% of the company's stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.